Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jan 7, 2005; 11(1): 41-45
Published online Jan 7, 2005. doi: 10.3748/wjg.v11.i1.41
Published online Jan 7, 2005. doi: 10.3748/wjg.v11.i1.41
Table 1 Incidence of gastric tumors in different treatment groups.
| Group | Treatment | Total No. of rats | No. of rats with tumor | Tumor incidence (%) |
| A | Control | 5 | 0 | 0 |
| B | MNNG alone | 16 | 12 | 75.01 |
| C | MNNG+celecoxib 5 mg/kg | 17 | 12 | 70.6 |
| D | MNNG+celecoxib 10 mg/kg | 16 | 3 | 18.8 |
| E | MNNG+celecoxib 20 mg/kg | 16 | 5 | 31.3 |
| F | MNNG+indomethacin 3 mg/kg | 16 | 11 | 68.8 |
- Citation: Yu J, Tang BD, Leung WK, To KF, Bai AH, Zeng ZR, Ma PK, Go MY, Hu PJ, Sung JJ. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention. World J Gastroenterol 2005; 11(1): 41-45
- URL: https://www.wjgnet.com/1007-9327/full/v11/i1/41.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i1.41